WT-1312 is under clinical development by Wintermute Biomedical and currently in Phase I for Herpes Zoster (Shingles). According to GlobalData, Phase I drugs for Herpes Zoster (Shingles) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WT-1312’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WT-1312 overview

WT-1312 is under development for the treatment of herpes zoster (shingles). The drug candidate is administered topically. The drug candidate is formulated as an antimicrobial lotion which is composed of effective amounts of L- arginine, undecylenic acid and Rheum officinale extract.

It was also under development for the treatment of wound infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and fungal infections including Candida albicans.

Wintermute Biomedical overview

Wintermute Biomedical is a global biopharmaceutical company that whose sole focus is to develop next-generation antibiotics in order to address the impending threat of antimicrobial resistance. The company is headquartered in Melbourne, Victoria, Australia.

For a complete picture of WT-1312’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.